
Dignify Therapeutics, a US-based company, innovates drug therapies for bladder and bowel disorders.
Dignify Therapeutics, founded in Durham, North Carolina, is dedicated to developing novel drug therapies for bladder and bowel disorders, particularly targeting patient populations with spinal cord injuries, multiple sclerosis, and similar conditions. The company's core mission is to improve the quality of life for individuals suffering from these debilitating disorders through innovative pharmaceutical solutions.
Key figures associated with Dignify Therapeutics include experienced professionals in the fields of drug development and neurology. The company has garnered attention and support from notable investors in the biotech sector. Among its achievements, Dignify Therapeutics has made significant strides in preclinical and clinical trials, demonstrating the potential impact of its therapies on patient care and quality of life.

Acorda Therapeutics
acorda.com

Denali Therapeutics

NeuroTherapeutics Pharma

Aptinyx
aptinyx.com

Axonis Therapeutics

Solace Therapeutics

Akttyva Therapeutics
akttyva.com

DiscGenics
discgenics.com

Drive Therapeutics

Spinogenix
spinogenix.com

Pliant Therapeutics
pliantrx.com

Rainier Therapeutics

NeuroPro Therapeutics

Psy Therapeutics
psythx.com

Dose Therapeutics
Companies similar to Dignify Therapeutics include Acorda Therapeutics, Denali Therapeutics, NeuroTherapeutics Pharma and Aptinyx.
Dignify Therapeutics was founded in 2013.
Dignify Therapeutics' headquarters is located in Durham, NC, US.
Dignify Therapeutics' most recent funding round was for $3.6M (USD) in March 2019.
As of Mar 1, 2019, Dignify Therapeutics has raised a total of $10.2M (USD).
Dignify Therapeutics has 9 employees as of Feb 5, 2024.